menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Removing Gut Bacteria’s Potential ‘Safe House’ May Lower Risk of Colorectal Cancer Subtype

ReachMD Healthcare Image
05/10/2024
eurekalert.org

Study led by researchers at Brigham and Women’s Hospital found an association between appendix removal and a decreased risk of colorectal cancer positive for tumor-promoting bacteria

The appendix, once dismissed as an unnecessary human organ, has more recently been shown to play a role in the immune system. However, we lack a clear understanding of how its removal to treat appendicitis affects long-term human health.  A new study from researchers at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, found that an appendectomy – a surgical procedure to remove the appendix – was linked with a reduced risk of a certain type of colorectal cancer, characterized by the presence of a likely tumor-promoting bacteria called Fusobacterium nucleatum. Results are published in Annals of Surgery.

“Appendicitis is a painful and often urgent condition that predominantly affects teens and young adults, and appendectomies are the go-to treatment. However, the long-term effects of this procedure on the gut microbiome and, in turn, risk of colorectal cancer, have been unclear,” said senior author Shuji Ogino, MD, PhD, a physician and researcher in the Department of Pathology at BWH. “We found that individuals who had undergone appendectomies had a significantly lower risk of acquiring this subtype of colorectal cancer.” 

In future research, Ogino’s lab aims to investigate the impact of appendectomies on colorectal neoplasms containing other potentially pathogenic bacteria. They also hope to explore the appendix’s role in contributing bacteria to the gut microbiome and how its absence influences different facets of human health.

The research team included co-first authors Hidetaka Kawamura, MD, PhD, Tomotaka Ugai, MD, PhD, Yasutoshi Takashima, MD, PhD, Kazuo Okadome, MD, PhD, from the Department of Pathology. Researchers gathered data from two large prospective cohort studies: the Nurses’ Health Study, involving 121,700 women aged 30-55 at enrollment, and the Health Professionals Follow-up Study, including 51,529 men aged 40-75 at enrollment. Participants provided information on lifestyle and health every two years. The team analyzed data from 91,975 women and 47,431 men who reported the presence or absence of an appendectomy history after excluding those with a history of cancer, inflammatory bowel disease, or implausible caloric intake. The team has followed up with 139,406 participants from both cohorts up to date or until they passed away. 

Among 2,811 incident colorectal cancer cases, 1,065 had tissue available for analyzing the bacterium Fusobacterium nucleatum. The research team’s findings revealed that those who had an appendectomy had a 47% lower risk of developing Fusobacterium nucleatum-positive colorectal cancer compared to those who hadn't undergone the procedure. There was no increase by the procedure in the risk of developing colorectal cancer overall or by cancer subtypes.

Limitations include that participants were predominantly white and non-Hispanic. Researchers had information only on appendectomies that had been performed by the time of the specific questionnaire. They could not incorporate the impact of appendectomies performed after that time; however, appendectomies are most commonly performed between the ages of 15 and 30 years, and participants were of a median age of 58 years for women and 53 years for men at the time of the specific questionnaire. They excluded colorectal cancer cases that had occurred before the specific questionnaire time; however, researchers note that this number was relatively small. Finally, bacterial data were not available for all colorectal cancer cases. 

“In our study, we examined the link between appendectomies and colorectal cancers positive for a specific strain of bacteria. However, many types of bacteria contribute to tumor development, and the full spectrum of bacteria the appendix harbors remains unclear. Thus, we cannot definitively say whether removing an organ considered to be a potential ‘safe house’ for certain bacteria always affects colorectal cancer risk positively or negatively, nor can we recommend removing it preventatively,” said Ogino. “We understand that the appendix plays a role in immune function, and our research aims to shed more light on the appendix's role in the body and how its removal impacts our overall health in the long term."

Authorship: In addition to Ogino and the paper’s co-first authors, BWH authors include Takashi Shimizu, Naohiko Akimoto, Koichiro Haruki, Kota Arima, Melissa Zhao, Juha Väyrynen, Xuehong Zhang, Jonathan Nowak, Marios Giannakis and Andrew Chan.

Disclosures: Andrew Chan previously served as a consultant for Bayer Healthcare and Pfizer Inc. Marios Giannakis was on an advisory board for AstraZeneca and receives research funding from Bristol-Myers Squibb. Jeffrey Meyerhardt has served as an advisor/consultant to Merck Pharmaceuticals and COTA Healthcare. Kana Wu is currently a stakeholder and employee of Vertex Pharmaceuticals. This study was not funded by any of these commercial entities.

Funding: This work was supported by U.S. National Institutes of Health (NIH) grants (P01 CA87969; UM1 CA186107; P01 CA55075; UM1 CA167552; U01 CA167552; R01 CA137178 to A.T.C.; K24 DK098311 to A.T.C.; R35 CA197735 to S.O.; R50 CA274122 to T.U.); by Cancer Research UK Grand Challenge Award (C10674 / A27140, to M.G., C.H., W.S.G., and S.O.); by an ASCO Conquer Cancer Foundation Career Development Award (to M.G.); by grants from the Prevent Cancer Foundation and American Institute for Cancer Research (to T.U.); and by the Stand Up to Cancer Colorectal Cancer Dream Team Translational Research Grant (SU2C-AACR-DT22-17 to M.G.), administered by the American Association for Cancer Research, a scientific partner of SU2C.  H.K. and T.U. were supported by fellowship grants from the Uehara Memorial Foundation.  The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.  The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. 

Paper cited: Kawamura H.et al. “Appendectomy and Long-term Colorectal Cancer Incidence, Overall and by Tumor Fusobacterium nucleatum Status.” Annals of Surgery DOI: 10.1097/SLA.0000000000006315



Journal

Annals of Surgery

Method of Research

Observational study

Subject of Research

People

Article Title

Appendectomy and Long-term Colorectal Cancer Incidence, Overall and by Tumor Fusobacterium nucleatum Status.

Article Publication Date

6-May-2024

COI Statement

Andrew Chan previously served as a consultant for Bayer Healthcare and Pfizer Inc. Marios Giannakis was on an advisory board for AstraZeneca and receives research funding from Bristol-Myers Squibb. Jeffrey Meyerhardt has served as an advisor/consultant to Merck Pharmaceuticals and COTA Healthcare. Kana Wu is currently a stakeholder and employee of Vertex Pharmaceuticals. This study was not funded by any of these commercial entities.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Facebook Comments

Schedule26 May 2024